Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2022; 10(18): 6198-6204
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6198
Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature
Kai Liu, Jian-Feng Bao, Tao Wang, Hao Yang, Bao-Ping Xu
Kai Liu, Department of Radiotherapy, Traditional Chinese Hospital of Lu’an affiliated to Anhui University of Traditional Chinese Medicine, Lu’an 237000, Anhui Province, China
Jian-Feng Bao, Department of Immunology, Xixi Hospital of Hangzhou affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou 310023, Zhejiang Province, China
Tao Wang, Department of Urology, Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Zhongshan 528401, Guangdong Province, China
Hao Yang, Bao-Ping Xu, Department of Critical Care Medicine, Traditional Chinese Hospital of Lu’an affiliated to Anhui University of Traditional Chinese Medicine, Lu’an 237000, Anhui Province, China
Author contributions: Xu BP and Liu K designed the study and drafted the manuscript; Wang T and Yang H collected and analyzed the data; Xu BP and Bao JF revised the manuscript critically for important intellectual content; all authors reviewed and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 81873317; the Natural Science Foundation of Zhejiang, No. LSY19H030002; and the Science and Technology Projects of Hangzhou City, No. 20181228Y22.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Ping Xu, MD, Professor, Department of Critical Care Medicine, Traditional Chinese Hospital of Lu’an affiliated to Anhui University of Traditional Chinese Medicine, No. 76 Renmin Road, Lu’an 237000, Anhui Province, China. xu131406@qq.com
Received: November 9, 2021
Peer-review started: November 9, 2021
First decision: December 27, 2021
Revised: January 13, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: June 26, 2022
Processing time: 219 Days and 14.1 Hours
Core Tip

Core Tip: Since its approval in 2019 by the National Drug Administration, camrelizumab (SHR-1210), a programmed cell death 1 inhibitor, is in wide clinical use as a therapeutic option for various tumor types. Until now, allergic reactions induced by camrelizumab have been rarely reported from various studies. For the first time, we report a case of camrelizumab-induced anaphylactic shock in a patient with esophageal squamous cell carcinoma.